Most importantly, cisplatin combined with FGFR2 inhibition decreased the percentage of CD44high/ALDH1high, and no CSCs enrichment was noticed after cisplatin exposure, indicating that blocking FGFR is an attractive target to eliminate the CSCs in HNSCC[115]. This evidence concerns the gene FGFR2 and head and neck squamous cell carcinoma.